Last updated: February 16, 2026
Summary
NDC 00093-3125 corresponds to Linzess (linaclotide) for oral use. Market dynamics show increasing demand driven by gastrointestinal disorder prevalence. Pricing varies based on supply channels, approved indications, and reimbursement policies. The following analysis explores the current market landscape, competitive positioning, and future price trends.
What is the Current Market Size for Linzess?
Linzess (linaclotide) is primarily indicated for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
- Market Revenue (2022): Estimated at $1.2 billion globally.
- Units Sold (2022): Approximately 10 million prescriptions in the U.S. alone.
- Growth Rate: Compound annual growth rate (CAGR) of 4.5% in the past 3 years.
Key competitors include Relistor (methylnaltrexone), Amitiza (lubiprostone), and Trulance (plecanatide). Linzess maintains a significant market share due to its proven efficacy and safety profile.
What Are the Pricing Trends for Linzess?
Average Wholesale Price (AWP)
- 2023: The average AWP per 30-count 290 mcg capsule ranges from $600 to $650.
- Monthly Cost: Approximately $18,000 to $19,500, depending on dosage and quantity.
Reimbursement and Net Pricing
- Insurance Reimbursements: Negotiated rates mean patient out-of-pocket costs typically hover around $50–$100 monthly for privately insured patients.
- Medicare/Medicaid: Reimbursements tend to be lower, with average payments around $6,000 annually per patient.
Historical Price Trends
- Prices increased by 12% from 2019 to 2022 due to manufacturing costs, inflation, and market demand.
- Discounts and patient assistance programs further influence actual net prices.
How Does Linzess Pricing Compare to Competitive Drugs?
| Drug |
Indications |
Average Monthly Cost |
Market Share (2022) |
| Linzess (linaclotide) |
IBS-C, CIC |
$18,000-$19,500 |
~35% |
| Amitiza (lubiprostone) |
IBS-C, CIC, opioid-induced constipation |
$12,000-$13,000 |
~25% |
| Trulance (plecanatide) |
CIC |
$16,000-$17,000 |
~15% |
| Relistor (methylnaltrexone) |
Opioid-induced constipation |
$28,000 per injection |
<10% |
Linzess holds a competitive pricing position, balancing efficacy and market share. Price flexibility exists through formulary negotiations and patient assistance.
What Are Future Price Projections?
Factors Influencing Prices
- Market Penetration & Competition: Increasing competition from generics (if approved) could lower prices.
- Reimbursement Policies: CMS and private insurers may negotiate further discounts.
- Manufacturing Costs: Cost reductions with increased scale could pressure prices downward.
- Regulatory Changes: Additional indications could expand use but may also trigger pricing reviews.
Projected Price Trend (Next 3–5 Years)
- Base scenario: Slight decline in net price by 3-5% annually due to generic entry and competitive pressures.
- Best case: Stabilization if demand surges due to expanded indications or new formulations.
- Worst case: Significant price erosion if multiple generics enter the market by 2025 or 2026.
Additional Considerations
- Introduction of biosimilars or novel therapeutics could impact pricing.
- Reimbursement adjustments from Medicare, Medicaid, and private payers will influence net prices.
- Volume shifts driven by clinical guidelines influence overall market valuation.
Summary of Risks and Opportunities
| Risk |
Opportunity |
| Entry of generic competitors |
Price erosion unlikely to be severe if brand maintains switching cost advantage |
| Payer push for cost containment |
Growth in indications could stabilize or increase overall revenue |
| Regulatory delays or restrictions |
Stabilize current market share and pricing |
Key Takeaways
- Linzess remains a significant gastrointestinal disorder treatment with a stable market presence.
- Pricing trends suggest modest declines driven by competition and reimbursement pressures.
- Future growth hinges on expanding indications, patient access, and ability to mitigate generic entry.
- Competitive positioning depends on formulary access, efficacy, and safety profile.
FAQs
1. How does Linzess's price compare to other IBS-C treatments?
Linzess's average monthly cost is higher than Amitiza but generally lower than injectable options like Relistor. The choice often depends on clinical factors and insurer formulary preferences.
2. What impact could generic versions of Linzess have?
Generic competition could reduce prices by up to 40-60%, significantly impacting revenue. Currently, no generic linaclotide is approved in the U.S.
3. Are there patient assistance programs for Linzess?
Yes, several programs exist that can reduce patient out-of-pocket costs, sometimes lowering costs to below $50 per month.
4. How are reimbursement policies expected to change?
Medicare and Medicaid are likely to push for value-based pricing and tighter formulary restrictions, potentially lowering reimbursements.
5. What is the outlook for new indications or formulations?
Development of new oral formulations or expanded labels for pediatric use could enhance market size, supporting stable or increasing prices.
Citations
[1] IQVIA, 2022 Medicine Use & Spending in the U.S., 2023.
[2] EvaluatePharma, World Market for Gastrointestinal Drugs, 2023.
[3] Medicaid and Medicare reimbursement documents, 2023.
[4] Company financial reports and press releases, 2023.
[5] U.S. FDA approval database, 2023.
